Coverage reference
Does Medicare cover GLP-1 drugs? (2026)
A source-cited reference for Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus and the rest — what standard Part D excludes, what it covers, and the 2026 changes that move faster than most billing references keep up with.
Last verified · Reviewed by the D3rx Clinical Billing Team. Coverage policy is evolving — confirm against the source links before relying on it.
The bottom line
Medicare GLP-1 coverage is driven by the diagnosis, not the drug.
- ExcludedWeight loss: standard Medicare Part D cannot cover a GLP-1 prescribed solely for obesity/weight loss (statutory exclusion).
- CoveredType 2 diabetes: Part D does cover GLP-1s for diabetes (e.g. Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza) — subject to the plan's formulary and PA.
- Covered*CV risk / OSA / MASH: Wegovy (cardiovascular risk, MASH) and Zepbound (OSA) are Part-D-coverable for those indications — not for weight loss alone.
- 2026 BridgeObesity, via demo: the temporary Medicare GLP-1 Bridgecovers select obesity GLP-1s (~$50/month) outside standard Part D — see below.
- Not Part BBenefit: these are self-administered, so they are Part D (pharmacy) drugs — a Part B office-administration claim will deny.
By drug
| Brand | Medicare status |
|---|---|
| Ozempic | CoveredCovered (Part D) for type 2 diabetes |
| Wegovy | ConditionalExcluded for weight loss; covered for its non-weight-loss indication (CV/OSA/MASH) |
| Rybelsus | CoveredCovered (Part D) for type 2 diabetes |
| Mounjaro | CoveredCovered (Part D) for type 2 diabetes |
| Zepbound | ConditionalExcluded for weight loss; covered for its non-weight-loss indication (CV/OSA/MASH) |
| Trulicity | CoveredCovered (Part D) for type 2 diabetes |
| Victoza | CoveredCovered (Part D) for type 2 diabetes |
| Saxenda | ExcludedExcluded from standard Part D (weight loss) — see GLP-1 Bridge |
| Byetta | CoveredCovered (Part D) for type 2 diabetes |
| Bydureon | CoveredCovered (Part D) for type 2 diabetes |
The detail
- Self-administered GLP-1s are covered under Medicare Part D (or an MA-PD plan), NOT Part B. Part B does not cover patient self-injected drugs, so billing Ozempic/Wegovy/etc. to Part B as an office-administered drug will deny.
- Medicare Part D is statutorily barred (SSA §1860D-2(e)(2)(A), incorporating the Medicaid excludable list at §1927(d)(2)(A)) from covering a drug 'when used for anorexia, weight loss, or weight gain'. So a standard Part D plan cannot cover a GLP-1 prescribed SOLELY for obesity/weight loss — obesity-only billing is the leading cause of Part D GLP-1 rejection. CMS declined in April 2025 to finalize a reinterpretation that would have allowed anti-obesity coverage.
- Because the exclusion is INDICATION-specific (not brand-specific), Part D DOES cover GLP-1s for an FDA-approved non-weight-loss indication: Ozempic/Rybelsus/Mounjaro/Trulicity/Victoza for type 2 diabetes; the weight-loss brands are coverable for their OWN non-weight-loss FDA indications — Wegovy for cardiovascular risk reduction and MASH, Zepbound for obstructive sleep apnea — each subject to formulary placement and PA. The submitted diagnosis, not the brand, drives coverage.
- 2026 update2026 UPDATE (time-sensitive): the temporary CMS 'Medicare GLP-1 Bridge' demonstration (CMMI) provides nationwide coverage of select GLP-1s for OBESITY to eligible Part D beneficiaries at roughly a $50/month copay via a separate central CMS pharmacy-POS pathway (NOT the Part D plan), running through Dec 31, 2027. It bypasses, but does not repeal, the statutory weight-loss exclusion. For an obesity-only GLP-1 on/after July 1, 2026, check Bridge eligibility rather than treating it as categorically excluded.
- 2026 update2026 UPDATE (time-sensitive): the broader BALANCE Model's Medicare Part D obesity-coverage component (originally slated for Jan 2027) was INDEFINITELY DELAYED — CMS announced on April 21, 2026 it would not proceed for 2027 after Part D sponsors representing the required 80% of enrollment (incl. UnitedHealth and CVS) declined. The Medicare GLP-1 Bridge, not Part D BALANCE, is the operative Medicare obesity pathway as of mid-2026.
Why the same molecule can be covered or excluded
semaglutide
tirzepatide
liraglutide
Same molecule, two uses: semaglutide is sold as Ozempic/Rybelsus (type 2 diabetes) vs Wegovy (obesity, plus FDA-approved CV-risk reduction and MASH); tirzepatide is Mounjaro (type 2 diabetes) vs Zepbound (obesity, plus FDA-approved OSA). Payers adjudicate by the dispensed brand/NDC AND the submitted diagnosis: E11.- routes to covered diabetes logic; an OSA or established-CVD/MASH diagnosis can route certain obesity-brand NDCs to a COVERED non-obesity pathway; E66.-/Z68.- routes to the anti-obesity logic that is statutorily excluded from standard Medicare Part D and PA-gated/often excluded commercially.
Wegovy (semaglutide 2.4mg) gained an FDA cardiovascular-risk-reduction indication on March 8, 2024 (reduce MACE in adults with established CVD and obesity/overweight; SELECT trial). CMS confirmed (HPMS memo Mar 20, 2024) that once an anti-obesity drug gains an additional medically-accepted indication it falls outside the Part D weight-loss exclusion and can be covered for that indication, subject to PA/step therapy/quantity limits.
Zepbound (tirzepatide) gained an FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity on December 20, 2024 (SURMOUNT-OSA) — the first drug approved for OSA. Plans increasingly maintain a separate Zepbound-for-OSA PA pathway distinct from the (often excluded) weight-loss pathway.
Not every obesity brand has a covered non-weight-loss 'escape hatch'. Wegovy (CV-risk/MASH) and Zepbound (OSA) do; Saxenda (liraglutide) does NOT — it is FDA-approved only for chronic weight management, so for Medicare it has no non-excluded indication (the diabetes liraglutide is the separate brand Victoza). Older diabetes agents (Victoza, Trulicity, Byetta, Bydureon) have no weight-loss indication. So a coverage answer must check the SPECIFIC brand's approved indications, not assume the molecule.
Frequently asked questions
- Does Medicare cover Ozempic, Mounjaro, or Rybelsus for type 2 diabetes?
- Because the exclusion is INDICATION-specific (not brand-specific), Part D DOES cover GLP-1s for an FDA-approved non-weight-loss indication: Ozempic/Rybelsus/Mounjaro/Trulicity/Victoza for type 2 diabetes; the weight-loss brands are coverable for their OWN non-weight-loss FDA indications — Wegovy for cardiovascular risk reduction and MASH, Zepbound for obstructive sleep apnea — each subject to formulary placement and PA. The submitted diagnosis, not the brand, drives coverage.
- Does Medicare cover Wegovy or Zepbound for weight loss?
- Medicare Part D is statutorily barred (SSA §1860D-2(e)(2)(A), incorporating the Medicaid excludable list at §1927(d)(2)(A)) from covering a drug 'when used for anorexia, weight loss, or weight gain'. So a standard Part D plan cannot cover a GLP-1 prescribed SOLELY for obesity/weight loss — obesity-only billing is the leading cause of Part D GLP-1 rejection. CMS declined in April 2025 to finalize a reinterpretation that would have allowed anti-obesity coverage.
- What is the Medicare GLP-1 Bridge?
- 2026 UPDATE (time-sensitive): the temporary CMS 'Medicare GLP-1 Bridge' demonstration (CMMI) provides nationwide coverage of select GLP-1s for OBESITY to eligible Part D beneficiaries at roughly a $50/month copay via a separate central CMS pharmacy-POS pathway (NOT the Part D plan), running through Dec 31, 2027. It bypasses, but does not repeal, the statutory weight-loss exclusion. For an obesity-only GLP-1 on/after July 1, 2026, check Bridge eligibility rather than treating it as categorically excluded.
- Are GLP-1 drugs billed to Medicare Part B or Part D?
- Self-administered GLP-1s are covered under Medicare Part D (or an MA-PD plan), NOT Part B. Part B does not cover patient self-injected drugs, so billing Ozempic/Wegovy/etc. to Part B as an office-administered drug will deny.
Sources
Need a payer-specific answer?
Ask D3 answers commercial, Medicaid, and Medicare GLP-1 questions with cited facts, or check a specific drug + payer in the PA lookup.